TABITUXIMAB BARZUXETAN INDIUM IN-111
UNII 8Q5VSJ6M23

Substance Identification & Data

This profile provides standardized clinical and technical data for Tabituximab Barzuxetan Indium In-111, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8Q5VSJ6M23.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
8Q5VSJ6M23
CAS Registry Number
N/A
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
TABITUXIMAB BARZUXETAN INDIUM IN-111
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
10232
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tabituximab Barzuxetan Indium In-111. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

111IN-OTSA-101
ANTI-FZD10 ADCC ENHANCED ANTIBODY (OTSA101) INDIUM IN-111
INDIUM IN-111 LABELED IMMUNOGLOBULIN G1, ANTI-(FRIZZLED RECEPTOR FRIZZLED-10) (HUMAN-MUS MUSCULUS MONOCLONAL OTSA101 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL OTSA101 LIGHT CHAIN, DIMER, COMPD. WITH N-((1S,2S)-2-(BIS(CARBOXYMETHYL)AMINO)CYCLOHEXYL)-N-((2R)-2-(BIS(CARBOXYMETHYL)AMINO)-3-(4-ISOTHIOCYANATOPHENYL)PROPYL)GLYCINE
TABITUXIMAB BARZUXETAN INDIUM IN-111

Technical Codes

INDIUM IN-111-RADIOLABELLED OTSA 101
OTSA-101-DTPA INDIUM IN-11